Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes.
Maria O LevitinLettie E RawlinsGabriela Sanchez-AndradeOsama A ArshadStephan C CollinsStephen J SawiakPhillip H IfflandMalin H L AnderssonCaleb P BuppEmma L CambridgeEve L CoomberIan EllisJohanna C HerkertHolly IronfieldLogan JoryPerrine F KretzSarina G KantAlexandra NeaversonEsther NibbelingChristine RowleyEmily ReltonMark SandersonEthan M ScottHelen StewartAndrew Y ShuenJohn SchreiberLiz TuckJames TonksThorkild TerkelsenConny van Ravenswaaij-ArtsPradeep VasudevanOlivia WengerMichael WrightAndrew DayAdam HunterMinal PatelChristopher J LelliottPeter B CrinoBinnaz YalcinAndrew H CrosbyEmma L BapleDarren W LoganMatthew E HurlesSebastian S GeretyPublished in: Brain : a journal of neurology (2023)
KPTN-related disorder is an autosomal recessive disorder associated with germline variants in KPTN (previously known as kaptin), a component of the mTOR regulatory complex KICSTOR. To gain further insights into the pathogenesis of KPTN-related disorder, we analysed mouse knockout and human stem cell KPTN loss-of-function models. Kptn-/- mice display many of the key KPTN-related disorder phenotypes, including brain overgrowth, behavioural abnormalities, and cognitive deficits. By assessment of affected individuals, we have identified widespread cognitive deficits (n=6) and postnatal onset of brain overgrowth (n=19). By analysing head size data from their parents (n=24), we have identified a previously unrecognised KPTN dosage-sensitivity, resulting in increased head circumference in heterozygous carriers of pathogenic KPTN variants. Molecular and structural analysis of Kptn-/- mice revealed pathological changes, including differences in brain size, shape, and cell numbers primarily due to abnormal postnatal brain development. Both the mouse and differentiated iPSC models of the disorder display transcriptional and biochemical evidence for altered mTOR pathway signalling, supporting the role of KPTN in regulating mTORC1. By treatment in our KPTN mouse model, we find that the increased mTOR signalling downstream of KPTN is rapamycin sensitive, highlighting possible therapeutic avenues with currently available mTOR inhibitors. These findings place KPTN-related disorder in the broader group of mTORC1 related disorders affecting brain structure, cognitive function, and network integrity.
Keyphrases
- white matter
- resting state
- stem cells
- cell proliferation
- functional connectivity
- preterm infants
- cerebral ischemia
- single cell
- gene expression
- multiple sclerosis
- machine learning
- copy number
- skeletal muscle
- brain injury
- oxidative stress
- dna damage
- body mass index
- single molecule
- drug induced
- subarachnoid hemorrhage
- dna repair
- blood brain barrier
- genome wide
- data analysis
- replacement therapy